Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges
- PMID: 30373404
- DOI: 10.1177/2168479018801566
Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges
Abstract
Background: Patient-facing digital technologies (also called "Patient Technology" [PT]) have the potential to serve a variety of functions in clinical trials, such as capturing clinical endpoints, engaging patients, and facilitating remote study conduct. However, these technologies are not yet accepted as mainstream research tools, and the opportunities, challenges, and facilitators associated with their implementation in clinical trials have not been fully characterized.
Methods: In order to understand the factors affecting PT adoption, the TransCelerate Patient Technology Initiative conducted a series of surveys, interviews, and focus groups with approximately 600 subject matter experts, including pharmaceutical company representatives, clinical trial investigators at a number of trial sites worldwide, and clinical trial participants. All interview and survey responses were blinded and aggregated by a third-party consultant and themes were extracted.
Results: There was general consensus around the potential value of patient-facing technology as a clinical research tool, though a variety of challenges faced by each stakeholder were discussed. Detailed accounts of opportunities (improved patient experience, compliance, and engagement; clinical trial efficiencies; improved data quality and insights) and barriers (organizational and corporate cultural challenges, business-related challenges, user willingness and burden, and regulatory challenges) are reported.
Conclusions: While the barriers to PT adoption explored here were numerous, they were also generally consistent. A number of proposals for establishing more holistic, collaborative, and strategic approaches to PT implementation in clinical trials are discussed. Such approaches could facilitate more effective, widespread adoption of PT, and thereby a more patient-centric clinical trial paradigm.
Keywords: TransCelerate; clinical trial technology; digital R&D; mHealth; patient centricity; patient-facing technologies.
Similar articles
-
Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.Clin Transl Sci. 2021 Mar;14(2):445-459. doi: 10.1111/cts.12910. Epub 2020 Nov 30. Clin Transl Sci. 2021. PMID: 33048475 Free PMC article. Review.
-
Optimizing the Use of Electronic Data Sources in Clinical Trials: The Technology Landscape.Ther Innov Regul Sci. 2017 Sep;51(5):551-567. doi: 10.1177/2168479017718875. Epub 2017 Jul 11. Ther Innov Regul Sci. 2017. PMID: 30231687
-
Investigator Experiences Using Mobile Technologies in Clinical Research: Qualitative Descriptive Study.JMIR Mhealth Uhealth. 2021 Feb 12;9(2):e19242. doi: 10.2196/19242. JMIR Mhealth Uhealth. 2021. PMID: 33576742 Free PMC article.
-
Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology.J Med Internet Res. 2021 Feb 3;23(2):e18119. doi: 10.2196/18119. J Med Internet Res. 2021. PMID: 33533725 Free PMC article.
-
Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care.J Am Coll Cardiol. 2018 Jun 12;71(23):2680-2690. doi: 10.1016/j.jacc.2018.03.523. J Am Coll Cardiol. 2018. PMID: 29880129 Review.
Cited by
-
Navigating the challenges of clinical trial professionals in the healthcare sector.Front Med (Lausanne). 2024 Jun 3;11:1400585. doi: 10.3389/fmed.2024.1400585. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38887672 Free PMC article. Review.
-
Cancer Patients' Perspectives and Requirements of Digital Health Technologies: A Scoping Literature Review.Cancers (Basel). 2024 Jun 21;16(13):2293. doi: 10.3390/cancers16132293. Cancers (Basel). 2024. PMID: 39001356 Free PMC article.
-
First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.Digit Biomark. 2021 Aug 5;5(2):183-190. doi: 10.1159/000517411. eCollection 2021 May-Aug. Digit Biomark. 2021. PMID: 34723071 Free PMC article. Review.
-
Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.Clin Transl Sci. 2021 Mar;14(2):445-459. doi: 10.1111/cts.12910. Epub 2020 Nov 30. Clin Transl Sci. 2021. PMID: 33048475 Free PMC article. Review.
-
Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study.JMIR Mhealth Uhealth. 2020 May 7;8(5):e16043. doi: 10.2196/16043. JMIR Mhealth Uhealth. 2020. PMID: 32379055 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical